ArticleCurrent treatment options in rheumatology2015
Management of gastrointestinal involvement in scleroderma.
Article in Current treatment options in rheumatology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed.
- Oral and Periodontal Manifestations in Systemic Sclerosis: A Comprehensive Review of Pathophysiology, Clinical Features, and Management Strategies.Oral health & preventive dentistry · 2026Review
- Severe scleroderma colopathy at initial diagnosis of systemic sclerosis in a young man: a case report.Frontiers in medicine · 2026Article
- Knowledge and perceptions of medical practitioners on the role of nutrition in systemic sclerosis.Journal of scleroderma and related disorders · 2026Article
- Expert recommendations for the management of refractory gastroesophageal reflux disease in systemic sclerosis: A report from the World Scleroderma Foundation (WSF) Gastrointestinal "Ad hoc committee".Journal of scleroderma and related disorders · 2026Article
- The Predilection of Specific Diseases to Affect Different Sections of the Esophagus.Life (Basel, Switzerland) · 2025Review
- Rheumatologists' Adherence to EULAR Recommendations for Systemic Sclerosis Treatment: Experience of a Single Center in Serbia.Journal of clinical medicine · 2025Article
- Demographics and clinical features associated with abnormal small bowel motility in systemic sclerosis.Rheumatology (Oxford, England) · 2025Article
- Bidirectional endoscopic and pharmacological approach for the treatment of severe right-sided colonic stool impaction.BMJ case reports · 2025Article
- Drug treatment strategies for erosive esophagitis in adults: a narrative review.Translational gastroenterology and hepatology · 2025Review
- Views of nutrition needs in patients with systemic sclerosis.Journal of scleroderma and related disorders · 2024Article
- Review
- Gastric dysrhythmias in patients with early systemic sclerosis: a cross-sectional study.Rheumatology advances in practice · 2024Article
- The frequency and clinical associations of opioid use in systemic sclerosis.Rheumatology advances in practice · 2024Article
- A survey of Australian rheumatologists' perspectives of nutrition needs in systemic sclerosis.Journal of scleroderma and related disorders · 2023Article
- Systemic sclerosis gastrointestinal dysmotility: risk factors, pathophysiology, diagnosis and management.Nature reviews. Rheumatology · 2023Review
- Systemic sclerosis.Lancet (London, England) · 2023Review
- Treatment of Severe Swallowing Dysfunction in Systemic Sclerosis with IVIG: Role of Antimuscarinic Antibodies.Journal of clinical medicine · 2022Article
- Gastrointestinal symptom severity and progression in systemic sclerosis.Rheumatology (Oxford, England) · 2022Article
- Management of scleroderma gastrointestinal disease: Lights and shadows.Journal of scleroderma and related disorders · 2022Review
- Relationship Between Gastrointestinal Transit, Medsger Gastrointestinal Severity, and University of California-Los Angeles Scleroderma Clinical Trial Consortium Gastrointestinal Tract 2.0 Symptoms in Patients With Systemic Sclerosis.Arthritis care & research · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Gastrointestinal tract (GIT) commonly affects patients with systemic sclerosis (SSc). The GI involvement is quite heterogeneous varying from asymptomatic disease to significant dysmotility causing complications like malabsorption, weight loss and severe malnutrition. This review focuses on the management of GI involvement in SSc and has been categorized based on the segment of GIT involved. A brief discussion on the role of patient reported outcome measures in SSc-GI involvement has also been incorporated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.